Eosinophilic Esophagitis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2016, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 3 respectively for Eosinophilic Esophagitis.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Eosinophilic Esophagitis Overview 7
Therapeutics Development 8
Pipeline Products for Eosinophilic Esophagitis - Overview 8
Eosinophilic Esophagitis - Therapeutics under Development by Companies 9
Eosinophilic Esophagitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Eosinophilic Esophagitis - Products under Development by Companies 13
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 14
Adare Pharmaceuticals, Inc. 14
Calypso Biotech SA 15
Celgene Corporation 16
DBV Technologies S.A. 17
Dr. Falk Pharma GmbH 18
Novartis AG 19
Panmira Pharmaceuticals, LLC. 20
Quorum Innovations LLC 21
Regeneron Pharmaceuticals Inc 22
Shire Plc 23
Eosinophilic Esophagitis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Allergen for Milk Allergy - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
AM-211 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AM-461 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
budesonide - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
budesonide - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CALY-002 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
dectrekumab - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
dupilumab - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
fluticasone propionate - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
fluticasone propionate - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Qi-201 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
RPC-4046 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Eosinophilic Esophagitis - Dormant Projects 58
Eosinophilic Esophagitis - Product Development Milestones 59
Featured News & Press Releases 59
Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy 59
Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions 59
Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis 60
Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children 61
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 61
Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 61
Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 62
May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 63
Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 64
May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 64
May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 65
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals, Inc., H2 2016 14
Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H2 2016 15
Eosinophilic Esophagitis - Pipeline by Celgene Corporation, H2 2016 16
Eosinophilic Esophagitis - Pipeline by DBV Technologies S.A., H2 2016 17
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016 18
Eosinophilic Esophagitis - Pipeline by Novartis AG, H2 2016 19
Eosinophilic Esophagitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016 20
Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H2 2016 21
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 22
Eosinophilic Esophagitis - Pipeline by Shire Plc, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Eosinophilic Esophagitis - Dormant Projects, H2 2016 58